Ozempic and the Body's Hidden Rewiring: Not Just Weight
A friend in Brussels described it to me once: she had started a GLP-1 medication, lost the weight she'd carried for years, felt genuinely well for the first time in a decade.
There is a particular kind of loss that nobody warns you about. Not dramatic, not dangerous — just quietly disorienting. A friend in Brussels described it to me once: she had started a GLP-1 medication, lost the weight she'd carried for years, felt genuinely well for the first time in a decade. And then one morning she realised that the espresso she had loved since university tasted flat. The smell of her grandmother's kitchen, replicated precisely at a café she'd found in Ixelles, no longer landed the way it should. She wasn't sick. She was just subtly different.
Research now suggests this is neither imagined nor rare. Studies indicate that GLP-1 drugs — semaglutide and its relatives, the medications behind Ozempic and Wegovy — may alter both taste and smell perception in some users. The mechanism isn't fully understood, but GLP-1 receptors exist throughout the nervous system, not just in the gut and pancreas. When you change the signalling, you change more than appetite. You change, it seems, the texture of experience.
What interests me more than the side effect itself is what the side effect reveals. We have been talking about these drugs almost entirely through the frame of weight — before and after photographs, BMI statistics, dress sizes. But the body is not a filing cabinet with one drawer labelled *fat*. GLP-1 medications appear to touch impulsivity, to reduce violent behaviour in some studies, to affect how alcohol registers as rewarding. They change what the brain reaches for. That is not a weight loss drug. That is something considerably more complex.
This complexity matters for anyone taking these medications and for anyone considering them. The research on reduced exercise motivation is worth sitting with — there is real evidence that some GLP-1 users move less, possibly because the drug suppresses the dopamine feedback loop that makes exertion feel rewarding. Weight loss without physical activity has limits. The body needs both, and a medication that delivers one while quietly undermining the other is presenting a problem that requires active management, not passive trust.
None of this is reason for alarm. The breast cancer reduction data is genuinely promising. The new oral formulation from AstraZeneca suggests these treatments will become less invasive and more accessible. The science is serious and moving fast.
But the body is a system, not a target. Treat it like one.
One thing to do: If you're taking a GLP-1 medication, schedule a deliberate conversation with your doctor specifically about exercise — not weight, not blood sugar, exercise. Ask whether your current movement levels have changed since starting, and whether your dose or timing could be adjusted to support staying active.
